SCHEMBL3824786

SCHEMBL3824786

CC(NCCc1ccccc1)C(N)=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 2/20 0.54
KMT2A Q03164 2/20 0.54
TSHR P16473 2/20 0.54
MEN1 O00255 1/20 0.54
OPRK1 P41145 1/20 0.50
CYP2D6 P10635 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
PARP1 P09874 1/20 0.47
CYP3A4 P08684 2/20 0.46
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
BLM P54132 1/20 0.46
GFER P55789 1/20 0.46
PMP22 Q01453 1/20 0.46
CA12 O43570 1/20 0.46
CA2 P00918 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6190817 1.00 SIGMAR1 (0.54) SIGMAR1KMT2ATSHRMEN1OPRK1
Hydrochloric Acid SCHEMBL5967359 0.98 SIGMAR1 (0.53) SIGMAR1KMT2ATSHRMEN1OPRK1
SCHEMBL10608616 0.90 CYP2D6 (0.58) SIGMAR1KMT2ACYP2D6CYP2C9CYP2C19
SCHEMBL10611156 0.90 CYP2D6 (0.58) SIGMAR1KMT2ACYP2D6CYP2C9CYP2C19
SCHEMBL10766683 0.90 CYP2D6 (0.58) SIGMAR1KMT2ACYP2D6CYP2C9CYP2C19
SCHEMBL2398120 0.86 KMT2A (0.66) SIGMAR1KMT2ATSHRMEN1OPRK1
SCHEMBL2398115 0.86 KMT2A (0.66) SIGMAR1KMT2ATSHRMEN1OPRK1
SCHEMBL7733774 0.85 MAPT (0.55) SIGMAR1KMT2ATSHRMEN1OPRK1
SCHEMBL7733778 0.85 MAPT (0.55) SIGMAR1KMT2ATSHRMEN1OPRK1
SCHEMBL9267311 0.84 SIGMAR1 (0.56) SIGMAR1KMT2ATSHRMEN1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2094646-A1 AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES AstraZeneca AB (SE) 2009-09-02 EP claimed
WO-2008075025-A1 AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES ASTRAZENECA AB (SE) 2008-06-26 WO claimed
EP-3154934-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES Université de Lille 2 Droit et Santé (FR) 2017-04-19 EP disclosed
WO-2015193255-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITION AND THEIR USE IN TREATING NEURODEGENERATIVE DISEASES UNIVERSITE DE LILLE 2 DROIT ET SANTE (FR) 2015-12-23 WO disclosed
EP-2094646-A1 AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES AstraZeneca AB (SE) 2009-09-02 EP disclosed
WO-2008075025-A1 AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES ASTRAZENECA AB (SE) 2008-06-26 WO disclosed
EP-1799645-A2 PROCESSES AND INTERMEDIATES FOR PREPARING CYSTEINE PROTEASE INHIBITORS Bayer Schering Pharma Aktiengesellschaft (DE) 2007-06-27 EP disclosed
WO-2006034004-A2 PROCESSES AND INTERMEDIATES FOR PREPARING CYSTEINE PROTEASE INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 2006-03-30 WO disclosed